CA19-9 Does Not Predict cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis Undergoing Liver Transplantion
Open accessThe DOI matches its Crossref record.
Abstract
The results of liver transplantation in patients with cholangiocarcinoma have been poor. It has been suggested that elevated serum CA19-9 levels predict cholangiocarcinoma in patients with primary sclerosing cholangitis. We analyzed the predictive value of CA19-9 antigen as a marker of cholangiocarcinoma in patients with primary sclerosing cholangitis evaluated for liver transplantation. We reviewed the charts of 26 patients with primary sclerosing cholangitis (stage IV) in whom preoperative serum CA19-9 levels were determined; 22 of 26 underwent liver transplant. Explant specimens were serially sectioned and examined for tumor. In 3 of the 26 patients, cholangiocarcinoma was diagnosed during pretransplantation evaluation; exploratory laparotomy on the last patient showed no evidence of cholangiocarcinoma, and this patient is awaiting transplantation. Twelve of the 26 patients had CA19-9 levels more than double the laboratory reference range (0-37 U/mL) (mean 183.1 +/- 103 U/mL, range 77-415 U/mL). Two of the 12 patients with elevated CA19-9 levels had cholangiocarcinoma. Of the 14 patients with normal levels, two had cholangiocarcinoma. No correlation between elevated CA19-9 and bile duct dysplasia was noted. Sensitivity for serum CA19-9 levels more than twice the reference range is 50%, specificity is 54.5%, positive predictive value is 16.6%. An elevated serum CA19-9 level in a patient with stage IV primary sclerosing cholangitis does not reliably predict coexisting cholangiocarcinoma. Persistently high or rising serum CA19-9 levels do not indicate more urgent need for liver transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
LIVER TRANSPLANTATION FOR CHOLANGIOCARCINOMA: RESULTS IN 207 PATIENTS1
Meyer, C. G., Penn, I., & James, L. (2000) · Transplantation · doi:10.1097/00007890-200004270-00019 · Cited by 502
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339
“However, other investigators have questioned the utility of this tumor marker in predicting development of cholangiocarcinoma or other pancreaticobiliary tumors due to a high falsepositivity rate (11, 18, 19).”
BackgroundCholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
Chalasani, N., Baluyut, A., Ismail, A., Zaman, A., Sood, G., Ghalib, R., McCashland, T. M., Reddy, R. K., Zervos, X., Anbari, M. A., et al. (2000) · Hepatology · doi:10.1002/hep.510310103 · Cited by 336
Sudan, D., DeRoover, A., Chinnakotla, S., Fox, I., Shaw, B., McCashland, T., Sorrell, M., Tempero, M., & Langnas, A. (2002) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2002.20812.x · Cited by 314
Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
Metadata
- Authors
- Fisher, A., Theise, N. D., Min, A., Mor, E., Emre, S., Pearl, A., Schwartz, M. E., Miller, C. M., & Sheiner, P. A.
- Venue
- Liver Transplantation and Surgery
- Publisher
- Wiley
- Published
- 1995-03
- Volume
- 1
- Issue
- 2
- Pages
- 94-98
- ISSN
- 1074-3022 (ISSN-L)
- OpenAlex
- W2085747281
- Cited by
- 44
- References
- 0
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CA19-9 Does Not Predict cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis Undergoing Liver Transplantion. https://app.cochat.ai/papers/10.1002/lt.500010204
- The paper
- Fisher, A., Theise, N. D., Min, A., Mor, E., Emre, S., Pearl, A., Schwartz, M. E., Miller, C. M., & Sheiner, P. A. (1995). CA19-9 Does Not Predict cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis Undergoing Liver Transplantion. Liver Transplantation and Surgery. https://doi.org/10.1002/lt.500010204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.